Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
Clinical trial NCT02184767 · COMPLETED
Trial details
- NCT number
- NCT02184767
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-01
- Primary completion
- 2015-03-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.